Alloy Therapeutics Inks a Pact with Takeda to Develop Cell Therapy Platform
Shots:
- Alloy Therapeutics has entered into a strategic collaboration and licensing agreement with Takeda to develop the latter’s induced pluripotent stem cell (iPSC) driven CAR-T cell platform (iCAR-T) and CAR-NK platform (iCAR-NK)
- As per the agreement, Alloy will advance therapies for solid and hematological cancers, securing co-exclusive rights to commercialize iCAR-T and iCAR-NK products for the same indication
- Alloy will enhance the iCAR-T/NK platform using synergies across its unique business model, enabling broader access for biotech and pharma partners to develop cancer therapies, while pursuing clinical validation and improvements of the platform
Ref:Pharma | Image: Alloy Therapeutics
Related News:- Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
